Nanoparticle Immunotherapy for Lung Cancer
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
This project is developing a new nanoparticle-based immunotherapy called ARAC-02 to improve outcomes for people with non-small cell lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pdx Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project ID | NIH-11184418 on NIH RePORTER |
What this research studies
For patients with non-small cell lung cancer, current treatments often involve harsh drugs and radiation, with limited long-term success. This project focuses on ARAC-02, a new type of immunotherapy that uses tiny nanoparticles to deliver multiple agents directly to cancer cells. These nanoparticles are designed to kill cancer cells, release signals that activate the immune system, and block proteins that prevent the immune system from fighting the tumor. The goal is to create a powerful anti-tumor immune response that could lead to better results than existing therapies.
Who could benefit from this research
Good fit: Patients with non-small cell lung cancer who have not responded well to current immune checkpoint inhibitors or are seeking new treatment approaches might be ideal candidates for future clinical trials.
Not a fit: Patients without non-small cell lung cancer or those whose cancer does not involve the specific immune pathways targeted by ARAC-02 may not receive direct benefit from this particular therapy.
Why it matters
Potential benefit: If successful, this new immunotherapy could offer a more effective and potentially curative treatment option for many patients with non-small cell lung cancer.
How similar studies have performed: This approach builds on prior successful research, including a highly-rated initial grant phase, published data in Nature Communications, and a US patent for the ARAC-02 technology.
Where this research is happening
Portland, UNITED STATES
- Pdx Pharmaceuticals, INC. — Portland, United States (Active)
Researchers
- Principal investigator: Ngamcherdtrakul, Worapol — Pdx Pharmaceuticals, INC.
- Study coordinator: Ngamcherdtrakul, Worapol
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.